NCT02237209 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSV LID ΔM2-2 Vaccine

10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

BIOLOGICAL

Placebo Vaccine

0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

Trial Locations (7)

Johns Hopkins University Center for Immunization Research, Baltimore

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

Univ. of Colorado Denver NICHD CRS, Aurora

Usc La Nichd Crs, Alhambra

University of California, UC San Diego CRS, La Jolla

Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago

St. Jude Children's Research Hospital CRS, Memphis

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH